Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Peron 4190, Ciudad Autonoma de Buenos Aires, 1199, Buenos Aires, Argentina.
University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Rheumatol Int. 2019 Oct;39(10):1697-1702. doi: 10.1007/s00296-019-04433-2. Epub 2019 Aug 30.
Primary Sjögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma-and hypothetically other malignancies-may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer incidence for the general population was obtained from GLOBOCAN 2018, and demographic information was obtained from the national institute for statistics and census. Age- and sex-specific Standardized Incidence Ratio (SIR) were then calculated. One hundred fifty-seven patients, with a mean age of 57.8 years (SD 18.3), were included. Mean patient follow-up duration was 7.37 years (SD 4.2), contributing to a total of 1158 patient/years. Fifteen patients developed a malignancy during follow-up. Cancer incidence for pSS patients was compared with the general population's incidence through SIRs. Female patient's SIRs for overall cancer was 4.17 (95% CI 2.30-6.87), non-Hodgkin lymphoma 41.40 (95% CI 10.12-102.1), multiple myeloma 41.49 (95% CI 1.14-167.28), tongue cancer 44.4 (95% CI 1.23-177.31), uterus cancer 8.39 (95% CI 0.19-40.73), lung cancer 4.51 (95% CI 0.1-22.16), and breast cancer 3.76 (95% CI 1.04-9.45). An increased overall cancer risk, and particularly for non-Hodgkin lymphoma, multiple myeloma, breast cancer and tongue cancer was observed in female pSS patients compared to control group.
原发性干燥综合征(pSS)通常是一种轻度疾病,但可能会出现非霍奇金淋巴瘤等严重并发症——理论上也可能出现其他恶性肿瘤。本研究旨在评估与阿根廷一般人群相比,pSS 患者队列的总体和特定癌症发病率。这是一项回顾性分析研究,纳入了符合美国-欧洲共识组(AECG)标准的 pSS 患者,从诊断时开始随访,直至研究结束、死亡、失访或被诊断为癌症。一般人群的癌症发病率数据来自 GLOBOCAN 2018,人口统计信息来自国家统计局和人口普查局。然后计算年龄和性别特异性标准化发病率比(SIR)。共纳入 157 例患者,平均年龄 57.8 岁(标准差 18.3)。平均患者随访时间为 7.37 年(标准差 4.2),总计 1158 人年。随访期间有 15 例患者发生恶性肿瘤。通过 SIRs 将 pSS 患者的癌症发病率与一般人群的发病率进行比较。女性患者的总体癌症 SIR 为 4.17(95%可信区间 2.30-6.87),非霍奇金淋巴瘤为 41.40(95%可信区间 10.12-102.1),多发性骨髓瘤为 41.49(95%可信区间 1.14-167.28),舌癌为 44.4(95%可信区间 1.23-177.31),子宫癌为 8.39(95%可信区间 0.19-40.73),肺癌为 4.51(95%可信区间 0.1-22.16),乳腺癌为 3.76(95%可信区间 1.04-9.45)。与对照组相比,女性 pSS 患者的总体癌症风险增加,尤其是非霍奇金淋巴瘤、多发性骨髓瘤、乳腺癌和舌癌的风险增加。